297 related articles for article (PubMed ID: 10942634)
61. Therapeutic advances in the management of hepatitis B and hepatitis C.
Nguyen MH; Wright TL
Curr Opin Infect Dis; 2001 Oct; 14(5):593-601. PubMed ID: 11964881
[TBL] [Abstract][Full Text] [Related]
62. Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine?
Buti M; Cotrina M; Valdes A; Jardi R; Rodriguez-Frias F; Esteban R
J Hepatol; 2002 Mar; 36(3):445-6. PubMed ID: 11867193
[No Abstract] [Full Text] [Related]
63. Is it now the time to update treatment protocols for lymphomas with new anti-virus systems?
Luppi M; Barozzi P; Potenza L; Riva G; Morselli M; Torelli G
Leukemia; 2004 Oct; 18(10):1572-5. PubMed ID: 15284857
[No Abstract] [Full Text] [Related]
64. Hepatitis C virus infection in Taiwan: Past, present, and future.
Kao JH
J Formos Med Assoc; 2016 Feb; 115(2):65-6. PubMed ID: 26228687
[No Abstract] [Full Text] [Related]
65. Successful treatment of membranoproliferative glomerulonephritis associated with hepatitis B and C virus simultaneous infection patient.
Mima A; Iehara N; Matsubara T; Yamamoto S; Abe H; Nagai K; Matsuura M; Murakami T; Kishi S; Araoka T; Kishi F; Kondo N; Shigeta R; Yoshikawa K; Takahashi T; Kita T; Doi T; Fukatsu A
Clin Nephrol; 2010 Feb; 73(2):167-9. PubMed ID: 20129026
[No Abstract] [Full Text] [Related]
66. Persistence of YMDD variants after withdrawal of Lamivudine.
van der Eijk AA; Niesters HG; Pas SD; de Man RA
J Hepatol; 2002 Feb; 36(2):304-5. PubMed ID: 11830347
[No Abstract] [Full Text] [Related]
67. Lamivudine therapy in renal allograft recipients with hepatitis B virus infection.
Tsang WK; Tong KL; Chan HW
Transplant Proc; 2003 Feb; 35(1):278-9. PubMed ID: 12591398
[No Abstract] [Full Text] [Related]
68. Hepatitis B and C in the armed forces.
Freshwater DA
J R Army Med Corps; 2013 Sep; 159(3):169-74. PubMed ID: 24109138
[TBL] [Abstract][Full Text] [Related]
69. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same.
Herion D; Hoofnagle JH
Hepatology; 1997 Mar; 25(3):769-71. PubMed ID: 9049233
[No Abstract] [Full Text] [Related]
70. Therapy of acute and fulminant hepatitis B.
Tillmann HL; Patel K
Intervirology; 2014; 57(3-4):181-8. PubMed ID: 25034486
[TBL] [Abstract][Full Text] [Related]
71. A new class of pyrimidine nucleosides: inhibitors of hepatitis B and C viruses.
Shakya N; Vedi S; Liang C; Agrawal B; Tyrrell DL; Kumar R
Bioorg Med Chem Lett; 2012 Oct; 22(20):6475-80. PubMed ID: 22985854
[TBL] [Abstract][Full Text] [Related]
72. Lamivudine resistant occult HBV: implications for public health?
Bowden S; Bartholomeusz A; Locarnini S
J Hepatol; 2003 Apr; 38(4):526-8. PubMed ID: 12663248
[No Abstract] [Full Text] [Related]
73. Drugs for non-HIV viral infections.
Med Lett Drugs Ther; 1994 Apr; 36(919):27-32. PubMed ID: 8127252
[No Abstract] [Full Text] [Related]
74. [Lamivudine and alpha-IFN treatment of a severe case of acute hepatitis B].
Manciuc C; Vâţă A; Dorobăţ C; Scurtu R; Petrovici C; Luca V
Rev Med Chir Soc Med Nat Iasi; 2004; 108(1):207-9. PubMed ID: 15688787
[TBL] [Abstract][Full Text] [Related]
75. HIV and hepatitis virus resistance to antivirals: review of data from the XIX International HIV and Hepatitis Virus Drug Resistance Workshop and curative strategies.
Mascolini M; Mellors JW; Richman DD; Boucher CA; Larder BA
Antivir Ther; 2011; 16(2):263-86. PubMed ID: 21447877
[TBL] [Abstract][Full Text] [Related]
76. Hepatitis B and C Viruses and Biologics.
Grewal P; Sanghera R
Skin Therapy Lett; 2017 Jul; 22(4):7-9. PubMed ID: 28732153
[TBL] [Abstract][Full Text] [Related]
77. PGS consensus statement on management of hepatitis B virus infection--2003.
Abbas Z; Jafri W; Shah SH; Khokhar N; Zuberi SJ;
J Pak Med Assoc; 2004 Mar; 54(3):150-8. PubMed ID: 15129877
[No Abstract] [Full Text] [Related]
78. Recent advances in antiviral agents: antiviral drug discovery for hepatitis viruses.
Tanikawa K
Curr Pharm Des; 2006; 12(11):1371-7. PubMed ID: 16611121
[TBL] [Abstract][Full Text] [Related]
79. Excitement grows for potential revolution in hepatitis C virus treatment.
Opar A
Nat Rev Drug Discov; 2010 Jul; 9(7):501-3. PubMed ID: 20592732
[No Abstract] [Full Text] [Related]
80. Hepatitis C: infection and current treatment strategies.
Piascik P
J Am Pharm Assoc (Wash); 1997; NS37(4):376-8. PubMed ID: 9519644
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
